# Scientific program

## Scientific program

### Thursday, 4 May 2023

| | |
|---|---|
| 13:00-20:00 | **Registration** |
| 17:00-17:30 | **Welcome coffee** |
| 17:30-19:05 | **Opening ceremony** |
| | Welcome of the Guests |
| | Surprise performance |
| | Presentation "For HAE Patients" Award, Award Ceremony |
| 19:05-20:05 | **Opening lectures**<br>Chairs: Bruce Zuraw, Michael Kirschfink |
| I-01 | **Lactoferrin - the alarmin which knows when is a time to kill and a time to heal**<br>Vladimir Leksa |
| I-02 | **HAE with the plasminogen gene mutation K330E and other types of hereditary angioedema with normal C1-INH**<br>Konrad Bork |
| 20:05-22:05 | **Welcome reception** |

### Friday, 5 May 2023

| | |
|---|---|
| 08:00-10:00 | |
| 08:00-08:15<br>O-01 | **The Bradykinin cascade is activated in patients with Alzheimer's disease and is activated in vitro by aggregated Aβ protein**<br>Allen Kaplan |
| 08:15-08:30<br>O-02 | **C1 inhibitor deficiency is associated with a procoagulant phenotype in both humans and mice**<br>Steven Grover |

| | |
|---|---|
| 08:30-08:45<br>O-03 | **Th2 predominance and decreased NK cells in patients with hereditary angioedema – a connection with autoimmune disease?**<br>Linda Sundler Björkman |
| 08:45-09:00<br>O-04 | **Determining the effects of Moringa Oleifera on hepatic and monocytic cell lines in C1 esterase inhibitor production**<br>Martin Gonzo |
| 09:00-09:15<br>O-05 | **Purification and characterization of the C1 inhibitor R444C variant causing type 2 hereditary angioedema; covalent binding to human serum albumin and consequences**<br>József Dobó |
| 09:15-09:30<br>O-06 | **Cell-cell contacts and the glycocalyx are relevant structures in bradykinin-mediated endothelial barrier injury**<br>Robin Lochbaum |
| 09:30-09:45<br>O-07 | **Monocytes hyperactivity and endothelial dysfunction in hereditary angioedema: the MONOBRAD Study**<br>Nicolas Ozanne |
| 09:45-10:00<br>O-08 | **Biological pathway analyses of plasma proteomics in hereditary angioedema due to C1 inhibitor deficiency following lanadelumab treatment**<br>Dan Sexton |
| 10:00-10:30 | **Coffee break** |
| 10:30-12:10 | |
| 10:30-10:50<br>O-09 | **An updated and comprehensive classification and terminology of angioedema**<br>Avner Reshef |
| 10:50-11:05<br>O-10 | **Detection of Bradykinin and its major metabolites by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)**<br>Huamin Henry Li |
| 11:05-11:20<br>O-11 | **Diagnosis of angioedema by Artificial Intelligence**<br>Felix Aulenbacher |
| 11:20-11:35<br>O-12 | **SERPING1 splicing-affecting variants highly represented in the Czech cohort of HAE-1/HAE-2 patients**<br>Tomas Freiberger |

| | |
|---|---|
| 11:35-11:50<br>O-13 | **HAErmony-1: Clinical study of adeno associated virus vector-mediated gene therapy of human C1-inhibitor in Hereditary Angioedema Type I and II**<br>Marc Riedl |
| 11:50-12:10 | **Pregnancy consensus**<br>moderated by Teresa Caballero |
| 12:10-13:10 | **Lunch break** |
| 13:10-14:10 | |
| 13:10-13:30<br>I-03 | **CRISPR opens the way to genetic therapy of angioedema**<br>Despina Sanoudou |
| 13:30-13:45<br>O-14 | **Hereditary angioedema variant curation using a ClinGen framework**<br>Matija Rijavec |
| 13:45-14:00 | **International consensus on the use of genetics in the management of hereditary angioedema – The 2023 revision and update**<br>**Round table discussion and voting by Anastasios Germenis** |
| 14:00-16:00 | |
| P-01 | **One-year epidemiologic data from Angioedema Center Vienna, Austria**<br>Tamar Kinaciyan |
| P-02 | **Outcome parameters to measure efficacy of prophylactic therapy for hereditary angioedema: a systematic review**<br>Remy Petersen |
| P-03 | **Efficacy and safety of Lanadelumab in Russian participants with hereditary angioedema (HAE)**<br>Elena Latysheva |
| P-04 | **Mimics of hereditary angioedema in an emergency department**<br>Marko Barešić |
| P-05 | **Mechanistic modeling and simulations predict long-term HAE attack prevention with STAR-0215**<br>Jou-Ku Chung |
| P-06 | **The impact of dental procedures on angioedema attacks – An observational study of patients enrolled in the Romanian Hereditary** |

**Angioedema Registry**
Valentin Nadasan

P-07 **The analysis of the effect of the COVID-19 pandemic on C1-inhibitor deficient hereditary angioedema patients**
Dávid Szilágyi

P-08 **Clinical spectrum of high titre anti-Ro/SSA antibodies in patients with hereditary angioedema with C1 inhibitor deficiency**
Sladjana Andrejevic

P-09 **Efficacy and safety of rituximab in angioedema with acquired C1 inhibitor deficiency**
Galith Kalmi

P-10 **Hereditary angioedema in the Republic of Panama**
Olga M. Barrera

P-11 **Vascular neural control blockade in a COVID-19 positive hereditary angioedema patient**
Francesca Perego

P-12 **A value-based and human centred innovative approach based on persona: Psychosocial needs of hereditary angioedema patients and caregivers**
Francesca Perego

P-13 **Decreased adhesion to the endothelium leads to elevated neutrophil granulocyte count in hereditary angioedema patients**
Erika Kajdácsi

P-14 **Psychodynamic factors impacting the degree of trust in the relationship between a doctor and a HAE patient**
Ekaterina A. Viktorova

P-15 **Targeted sequencing panel for the diagnosis of hereditary angioedema due to C1 inhibitor deficiency**
Matija Rijavec

P-16 **Route of administration preferences of people with hereditary angioedema for on-demand treatment: A US-based qualitative study**
Laurence Boulliet

P-17 **Second patient with kininogen 1 mutation in hereditary angioedema**
Gaëlle Hardy

| | |
|---|---|
| P-18 | **A retrospective study (INTEGRATED) of real-world effectiveness of Lanadelumab in European patients with HAE Type I/II**<br>Markus Magerl |
| P-19 | **Quality of life in patients with hereditary angioedema in Latvia**<br>Kanepa Adine |
| P-20 | **Burden of hereditary angioedema type I and II: Preliminary results from a real-world study in Europe, Israel and Canada**<br>Henriette Farkas |
| P-21 | **Assisted reproductive techniques in patients with Bradykinin-induced angioedema**<br>Tatiana Navarro-Cascales |
| P-22 | **Prevalence of non-alcoholic steatohepatitis in adult patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH)**<br>Teresa Caballero |
| P-23 | **Possible psychological fluctuations in severity and frequency of hereditary angioedema swellings**<br>Tomaz Garcez |
| P-24 | **Real-life experience after eight months of long-term subcutaneous C1-inhibitor prophylactic treatment in four Hungarian patients with hereditary angioedema due to C1-inhibitor deficiency**<br>Hanga Réka Horváth |
| P-25 | **Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist PHVS416 in patients with hereditary angioedema attacks**<br>Marc A. Riedl |
| 16:30- | **Social program outside with discussion** |

## Saturday, 6 May 2023

| | |
|---|---|
| 08:00-09:30 | |
| 08:00-08:15<br>O-15 | **Attack-free status across subgroups of patients with hereditary angioedema (HAE) after 96 weeks of berotralstat treatment: results from the APeX-S trial**<br>Avner Reshef |

| | |
|---|---|
| 08:15-08:30<br>O-16 | **Rationale for the short-term prophylaxis regimen with Sebetralstat in KONFIDENT-S**<br>Michael Smith |
| 08:30-08:45<br>O-17 | **One-year results from an open-label study of Donidalorsen in patients with hereditary angioedema**<br>Laura Bordone |
| 08:45-09:00<br>O-18 | **The EC85 derived from the oral bradykinin B2 receptor antagonist PHA121 against bradykinin effects in healthy volunteers predicts the onset and duration of its clinical effects in hereditary angioedema**<br>Marcus Maurer |
| 09:00-09:15<br>O-19 | **Efficacy and safety of the oral bradykinin B2 receptor antagonist PHVS416 in treatment of hereditary angioedema attacks: topline results of RAPIDe-1 phase 2 trial**<br>Henriette Farkas |
| 09:15-09:30<br>O-20 | **Design of ALPHA-STAR, a Phase 1b/2 proof-of-concept trial of STAR-0215 as a long-active preventative therapy in patients with hereditary angioedema (HAE) Types I or II**<br>Marcus Maurer |
| 09:30-10:00 | **Coffee break** |
| 10:00-11:15 | |
| 10:00-10:15<br>O-21 | **Transient exposure to NTLA-2002, an investigational CRISPR/Cas9-based gene editing therapy, leads to durable pharmacodynamic responses and attack control in patients with hereditary angioedema**<br>Hilary Longhurst |
| 10:15-10:30<br>O-22 | **Prototype of a mobile application to record prodromes and attacks of hereditary angioedema**<br>Iris Leibovich-Nassi |
| 10:30-10:45<br>O-23 | **Garadacimab for hereditary angioedema prophylaxis: Long-term efficacy and safety from the VANGUARD Phase 3b open-label extension trial (first interim analysis)**<br>Avner Reshef |
| 10:45-11:00<br>O-24 | **Effect of prophylactic immunomodulation in non-human primates treated with BMN 331, an AAV5 gene therapy for hereditary angioedema**<br>Benjamin M. Hock |

| | |
|---|---|
| 11:00-11:15<br>O-25 | **Garadacimab for hereditary angioedema prophylaxis: Efficacy and safety from a Phase 2 open-label extension trial**<br>Timothy J. Craig |
| 11:15-11:45 | **Coffee break** |
| 11:45-13:00 | **Scientific Session VI.**<br>Chairs: Konrad Bork, Laurence Bouillet |
| 11:45-12:00<br>O-26 | **Prophylaxis of angioedema attacks due to acquired C1-Inhibitor deficiency with PHA121, a novel oral bradykinin B2 receptor antagonist**<br>Remy S. Petersen |
| 12:00-12:15<br>O-27 | **Patient case series of hereditary angioedema with normal C1 inhibitor and factor XII mutation: Findings from an Allergy and Immunology Department in Argentina**<br>Ricardo D. Zwiener |
| 12:15-12:30<br>O-28 | **Characteristics of acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH) at a large tertiary care hospital in Spain**<br>Patricia Mir Ihara |
| 12:30-12:45<br>O-29 | **Angioedema due to acquired C1-inhibitor deficiency associated to monoclonal gammopathies of undetermined significance - Characteristics of a French national cohort**<br>Delphine Gobert |
| 12:45-13:00<br>O-30 | **A novel diagnostic parameter for acquired C1-inhibitor deficiency**<br>Zsófia Godnic-Pólai |
| 13:00-14:00 | **Lunch break** |
| 14:00-15:30 | |
| 14:00-14:15<br>O-31 | **Long-term prophylaxis with Lanadelumab for children and adolescents with HAE**<br>Ekaterina A. Viktorova |
| 14:15-14:30<br>O-32 | **Is pre-procedural prophylaxis needed in patients receiving the newer HAE-C1INH prophylactic therapies?**<br>Teresa Caballero |
| 14:30-14:45<br>O-33 | **Quality of life, disease control and mental health in patients with hereditary angioedema in Slovakia – national online survey**<br>Milos Jesenak |

| | |
|---|---|
| 14:45-15:00<br>O-34 | **Effectiveness of an adapted treatment schedule for long-term prophylaxis in patients with HAE-C1-INH**<br>Johana Gil-Serrano |
| 15:00-15:15<br>O-35 | **Lanadelumab effectiveness and safety regardless of dosing and dosing changes in patients with hereditary angioedema from the United States and Canada: Real-world evidence from the EMPOWER Study**<br>Stephen D. Betschel |
| 15:15-15:30<br>O-36 | **HAE patients decision to carry on-demand treatment when away from home**<br>Stephen Betschel |
| 15:30-16:00 | **Coffee break** |
| 16:00-18:00 | |
| P-26 | **Evolution of health-related quality of life in patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) and its relationship with disease activity**<br>Ines Fernandez-Concha Llona |
| P-27 | **Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist PHA-022121**<br>Brigitte Loenders |
| P-28 | **Recombinant human C1 esterase inhibitor on-demand treatment for attacks of hereditary angioedema: A European registry update**<br>Anna Valerieva |
| P-30 | **Genetic segregation study in hereditary angioedema with normal C1-inhibitor due to F12 mutation in Southern Spanish population - an observational study**<br>Krasimira Baynova |
| P-31 | **Case report: Off-label long-term prophylaxis with C1-esterase-inhibitor (C1-INH) s.c. in a patient with acquired C1-INH-deficiency (C1-INH-AAE)**<br>Eva-Vanessa Ebert |
| P-32 | **Specific anti-spike IgG subclasses in patients with C1-INH-HAE (C1-esterase inhibitor deficiency hereditary angioedema) after different types of COVID-19 vaccines**<br>Petra Kiszel |

P-33 **Patients with hereditary angioedema comply with regular immunization? Pilot study**
Anete Grumach

P-34 **C1-INH complexes as markers for classical and lectin pathway activation and complex levels in angioedema patients**
Lisa Hurler

P-35 **Organization and patient activity**
Elena Bezbozhnaya

P-36 **Hereditary angioedema with normal C1 inbibitor and cutis laxa: An unusual association**
Regis Campos

P-37 **Development of HAE awareness in the Czech Republic**
Camelia Isaic

P-38 **Efficacy of the oral bradykinin B2 receptor antagonist PHVS416 by attack symptom in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks**
Anna Valerieva

P-39 **First report of FXII gene pathogenic variant in a Mexican family with hereditary angioedema**
Francisco Alberto Contreras

P-40 **Hereditary angioedema with a mutation in the plasminogen gene**
Signe Purina

P-41 **Experience in the use of pathogenetic therapy for arresting hereditary angioedema (HAE) attacks in pediatric patients**
Ekaterina A. Viktorova

P-42 **Prevailing swelling of the abdominal cavity, as an atypical course of HAE**
Liudmyla Zabrodska

P-43 **A patient who was diagnosed with hereditary angioedema at two different times**
Beáta Visy

P-44 **The patient journey: From mesenteric panniculitis and angioedema to acquired angioedema**
Ricardo Zwiener

| | |
|---|---|
| P-45 | **An uncommon case of postpartum venous thrombosis in a patient with C1INH-HAE**<br>Francesco Giardino |
| P-46 | **A young woman with C1-INH deficiency refractory to various treatments: The relevance of having all therapeutic strategies available**<br>Beatrice Piazza |
| P-47 | **Safety of COVID-19 vaccines in patients with angioedema with C1 inhibitor deficiency: Data from Italian Network for Hereditary and Acquired Angioedema (ITACA)**<br>Andrea Zanichelli |
| P-48 | **Garadacimab for hereditary angioedema prophylaxis in adolescents: Efficacy and safety from the VANGUARD Phase 3 and 3b open-label extension trial (first interim analysis)**<br>Markus Magerl |
| P-49 | **Transmission patterns in C1-INH deficiency hereditary angioedema favours a wild-type male offspring: Our experience at Chandigarh, India**<br>Ankur Jindal |
| P-50 | **Profile of Hereditary Angioedema from Nepal- A speck of imprint on Everest**<br>Dharmagat Bhattarai |
| 18:30- | **Social program outside with discussion** |

## Sunday, 7 May 2023

| | |
|---|---|
| 08:00-10:00 | **Scientific Session VIII.**<br>Chairs: Sladjana Andrejevic, Danny Cohn |
| 08:00-08:15<br>O-37 | **The ACARE network – An update on global angioedema projects and initiatives**<br>Marcus Maurer |
| 08:15-08:30<br>O-38 | **The angioedema registry of the Italian Network for Hereditary and Acquired Angioedema (ITACA): a tool to monitor HAE course, therapeutic adherence and overall burden of the disease**<br>Mauro Cancian |
| 08:30-08:45<br>O-39 | **The impact of puberty on C1INH-HAE course: A survey from the Italian Network for Hereditary and Acquired Angioedema (ITACA)**<br>Riccardo Senter |

| | |
|---|---|
| 08:45-09:00<br>O-40 | **Comorbidities in angioedema due to C1-INH deficiency: A survey from the Italian Network for Hereditary and Acquired Angioedema (ITACA)**<br>Andrea Zanichelli |
| 09:00-09:15<br>O-41 | **Pharmacoeconomic burden for HAE patients in Brazil**<br>Marina Teixeira Henriques |
| 09:15-09:30<br>O-42 | **Management of hereditary angioedema with normal C1Inh: About a series of 149 French cases**<br>Laurence Bouillet |
| 09:30-09:45<br>O-43 | **Diagnostic criteria of angiotensin converting enzyme inhibitors (ACEi) induced bradykinin angioedema: The experience from the French national reference center for angioedema**<br>Alexis Bocquet |
| 09:45-10:00<br>O-44 | **Autoimmune disorders in C1INH-hereditary angioedema: Preliminary data of a prospective study from an ITACA cohort**<br>Mauro Cancian |
| 10:00-10:30 | **Coffee break** |
| 10:30-11:30 | **Scientific Session IX.**<br>Chairs: Aharon Kessel, Andrea Zanichelli |
| 10:30-10:45<br>O-45 | **Health-related quality of life with garadacimab for hereditary angioedema prophylaxis: Results from a phase 2 trial**<br>Avner Reshef |
| 10:45-11:00<br>O-46 | **Quality of life in hereditary angioedema in Brazil: A multicentric study**<br>Lucca Nogueira Paes Jannuzzi |
| 11:00-11:15<br>O-47 | **Real-world effectiveness data on lanadelumab in HAE long term prophylaxis in Slovakia**<br>Anna Bobcakova |
| 11:15-11:30<br>O-48 | **Understanding the impact of HAE attacks on patient reported quality-of-life - analysis of real-world patient data**<br>David Hinds |
| 11:30-12:15 | |
| 11:30-12:00 | **'Grant for Young Investigators' Ceremony**<br>performed by Stephen Betschel |

| | |
|---|---|
| 12:00-12:10 | **Closing remarks**<br>performed by Allen Kaplan |
| 12:15-14:00 | **Lunch** |
| 14:00- | **Departure** |